• Explore /
  • Poster
  • / Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.

Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2– locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.

Abstract Poster

Authors

Hiroji Iwata

Hiroji Iwata

Aichi Cancer Center Hospital, Nagoya, Japan

Hiroji Iwata , José Baselga , Mario Campone , Carlos L. Arteaga , Javier Cortes , Walter Jonat , Michelino De Laurentiis , Eva Ciruelos , Wolfgang Janni , Thomas Bachelot , Per Eystein Lonning , Cynthia Ma , Ruth O'Regan , Emmanuelle Di Tomaso , Bharani Bharani-Dharan , Vincent Duval , Helen Lau , Caroline Germa , Patrick Urban , Angelo Di Leo

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2013 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer - HER2/ER

Track

Breast Cancer

Sub Track

ER+

Clinical Trial Registration Number

NCT01610284 and NCT01633060

Citation

J Clin Oncol 31, 2013 (suppl; abstr TPS650^)

DOI

10.1200/jco.2013.31.15_suppl.tps650

Abstract #

TPS650^

Poster Bd #

15A

Abstract Disclosures

Similar Posters

First Author: Angelo Di Leo

First Author: Gayathri Nagaraj

First Author: Ingrid A. Mayer

First Author: Joohyuk Sohn